A Randomised, Cross-over study to evaluate the bioequivalence and relative bioavailability of abiraterone acetate fine particle with methylprednisolone versus the reference product with prednisone in healthy subjects

Trial Profile

A Randomised, Cross-over study to evaluate the bioequivalence and relative bioavailability of abiraterone acetate fine particle with methylprednisolone versus the reference product with prednisone in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Methylprednisolone; Prednisone
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Jun 2017 New trial record
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top